HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (37) Citing Articles via Google Scholar Google Scholar Articles by Huang, S.-M. Articles by Lesko, L. J. Search for Related Content PubMed PubMed Citation Articles by Huang, S.-M. Articles by Lesko, L. J. Social Bookmarking                         What's this?

Drug-Drug, Drug-Dietary Supplement, and Drug-Citrus Fruit and Other Food Interactions: What Have We Learned?

From the Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research (CDER), Food and Drug Administration, Rockville, MD 20850.

Serious drug-drug interactions have contributed to recent U.S. market withdrawals and also recent nonapprovals of a few new molecular entities. Many of these interactions involved the inhibition or induction of metabolizing enzymes and efflux transporters, resulting in altered systemic exposure and adverse drug reactions or loss of efficacy. In addition to drug-drug interactions, drug-dietary supplement and drug-citrus fruit interactions, among others, could also cause adverse drug reactions or loss of efficacy and are important issues to consider in the evaluation of new drug candidates. This commentary reviews (1) the current understanding of the mechanistic basis of these interactions, (2) issues to consider in the interpretation of study results, and (3) recent labeling examples to illustrate the translation of study results to information useful for patients and health care providers.

Key Words: Drug-drug interaction • drug-dietary supplement interaction • drug-juice interaction • drug development • exposure-response relationship • labeling • risk management

Address for reprints: Shiew-Mei Huang, PhD, Office of Clinical Pharmacology and Biopharmaceutics, HFD-850, Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, PKLN 6A/19, Rockville, MD 20850.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S.-M. Huang, J. M. Strong, L. Zhang, K. S. Reynolds, S. Nallani, R. Temple, S. Abraham, S. A. Habet, R. K. Baweja, G. J. Burckart, et al. New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process J. Clin. Pharmacol., June 1, 2008; 48(6): 662 - 670. [Abstract] [Full Text] [PDF]

				S. Uchida, H. Yamada, X. D. Li, S. Maruyama, Y. Ohmori, T. Oki, H. Watanabe, K. Umegaki, K. Ohashi, and S. Yamada Effects of ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J. Clin. Pharmacol., November 1, 2006; 46(11): 1290 - 1298. [Abstract] [Full Text] [PDF]

				J. Y. Chien, A. Lucksiri, C. S. Ernest II, J. C. Gorski, S. A. Wrighton, and S. D. Hall STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE Drug Metab. Dispos., July 1, 2006; 34(7): 1208 - 1219. [Abstract] [Full Text] [PDF]

				M. F Paine, W. W Widmer, H. L Hart, S. N Pusek, K. L Beavers, A. B Criss, S. S Brown, B. F Thomas, and P. B Watkins A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction Am. J. Clinical Nutrition, May 1, 2006; 83(5): 1097 - 1105. [Abstract] [Full Text] [PDF]

				H. Derendorf, C. P. VanderMaelen, R.-S. Brickl, T. R. MacGregor, and W. Eisert Dipyridamole Bioavailability in Subjects With Reduced Gastric Acidity J. Clin. Pharmacol., July 1, 2005; 45(7): 845 - 850. [Abstract] [Full Text] [PDF]

				M. F. Paine, A. B. Criss, and P. B. Watkins Two Major Grapefruit Juice Components Differ in Time to Onset of Intestinal CYP3A4 Inhibition J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1151 - 1160. [Abstract] [Full Text] [PDF]